Abstract Background Ciltacabtagene autoleucel (cilta-cel) is a BCMA-directed chimeric antigen receptor (CAR) T-cell therapy approved for relapsed or refractory multiple myeloma (RRMM). Following the CARTITUDE-1 results in heavily pretreated patients, the randomized phase 3 CARTITUDE-4 trial demonstrated superior progression-free survival (PFS) and overall survival for cilta-cel compared with standard of care in lenalidomide-refractory patients after one to three prior lines, leading to label expansion in 2024. However, real-world data characterizing outcomes in this earlier-line indication are lacking. Methods We analyzed all patients with RRMM receiving standard-of-care cilta-cel between 2022 and 2025 from the German Registry for Stem Cell Transplantation and Cellular Therapy. Patients were stratified by prior lines of therapy into an Early group (1–3 prior lines) and a Late group (> 3 prior lines). The primary endpoint was PFS. Secondary endpoints included overall response rate, response conversion, and safety outcomes including cytokine release syndrome, immune effector cell-associated neurotoxicity syndrome (ICANS), non-ICANS neurotoxicity, and non-relapse mortality. Prognostic associations were assessed using restricted cubic spline Cox regression and univariable Cox models. Results Of 606 patients, 177 (30%) were treated in the Early and 429 (70%) in the Late setting. The overall response rate was 91% and 88%, with complete response in 63% and 54%, respectively. The 12-month PFS was 79% for Early and 70% for Late cilta-cel. Depth of response was the strongest predictor of PFS in both cohorts, with patients maintaining complete response showing 100% PFS at 12 months irrespective of treatment line. Extramedullary disease was adversely prognostic in both groups, whereas high-risk cytogenetics were not associated with inferior PFS in the Early group. Non-ICANS neurotoxicity occurred less frequently in the Early group (3% versus 8%), while non-relapse mortality was comparable (6% versus 7%). Conclusions This analysis demonstrates that cilta-cel in earlier lines of therapy achieves deep responses and high PFS consistent with the CARTITUDE-4 trial. These results provide real-world evidence for the deployment of cilta-cel as early as first relapse and may be a benchmark outside prospective trials.
Purpose: Anterior cruciate ligament (ACL) reconstruction using tendon grafts remains the standard treatment for ACL ruptures, although ligament-preserving techniques have gained increasing interest for selected injury patterns. This retrospective cohort study aimed to evaluate clinical and radiologic outcomes of a ligament-preserving ACL repair technique (Ligabrace), involving suture tape augmentation and cortical button fixation, compared with hamstring autograft reconstruction in patients with acute proximal ACL tears. Methods: A retrospective cohort of 50 patients with isolated acute proximal ACL rupture (Sherman I/II) without concomitant injuries was analyzed. Patients were allocated to either Ligabrace repair (n=25) or hamstring autograft reconstruction (n=25) based on intraoperative assessment of tissue quality. Clinical outcome measures (Tegner, Lysholm, and IKDC scores) were assessed preoperatively (T0) and at 12 months postoperatively (T2). In addition, magnetic resonance imaging (MRI) and clinical knee examinations, including instrumented anterior-posterior (AP) laxity measurements, were performed at defined follow-up intervals. Results: At 12 months (T2), no statistically significant differences were observed between groups in any of the evaluated outcome measures (p > 0.05). The Ligabrace group demonstrated mean Lysholm scores of 90.3 ± 7.9 (range 71 - 100) and IKDC scores of 87.1 ± 11.3 (range 62 - 100), comparable to the reconstruction group. Tegner activity levels were 6.2 ± 1.7 in the Ligabrace group and 5.8 ± 1.7 in the reconstruction group. Mean side-to-side AP laxity was 0.56 mm in the Ligabrace group and 0.72 mm in the reconstruction group. Conclusion: Primary ACL repair using the Ligabrace technique demonstrated comparable short-term clinical and radiologic outcomes to hamstring autograft reconstruction in a selected cohort of patients with acute proximal ACL tears. These findings should be interpreted considering the retrospective design and potential selection bias, and further prospective studies are warranted. Level of Evidence: Level III, retrospective cohort study
Die Deutsche Gesellschaft für Kardiologie – Herz- und Kreislaufforschung e. V. (DGK) legt hiermit eine Aktualisierung des Curriculums zur Erlangung einer Zusatzqualifikation Spezielle Rhythmologie vor, um besondere Kenntnisse, Erfahrungen und Fertigkeiten anzuerkennen. Die Neuerungen waren notwendig, um eine Angleichung an die Anforderungen der European Heart Rhythm Association (EHRA) zu erzielen. Neben dem Erwerb der Zusatzqualifikation Spezielle Rhythmologie (24 Monate) können auch die Bereiche Invasive Elektrophysiologie bzw. Aktive Herzrhythmusimplantate separat erworben werden (jeweils 15 Monate). Die Erteilung des Zertifikats setzt die Anerkennung als Facharzt für Innere Medizin und Kardiologie voraus. Beschrieben werden Ziele und die zugehörigen theoretischen und praktischen Inhalte des Programms. Zudem werden Kriterien für eine Stätte zur Erlangung der Zusatzqualifikation und für die Qualifikation des Leiters formuliert. Der Ablauf der Zusatzqualifikation wird in einem Logbuch dokumentiert. Persönliche Anerkennungen sowie die Zertifizierung von Stätten, Leitern und stellvertretenden Leitern erfolgt durch Gutachter bzw. durch das Gremium Spezielle Rhythmologie der DGK. Eine Rezertifizierung von Stätten und persönlichen Anerkennungen erfolgt nach 7 Jahren, ausgenommen davon sind bereits im Rahmen der Übergangsregelung unbefristet erteilte persönliche Anerkennungen der Zusatzqualifikation.